There’s never been a time when science and technology have formed such a powerful union as they do now. We’re able to identify drug discovery targets using genomics and AI/ML in a way that is unprecedented. We’re also able to use more approaches than ever before to design new medicines and vaccines to address the root cause of disease.
Innovation
Ahead of disease
Innovation is at the heart of achieving our purpose – to unite science, technology and talent to get ahead of disease together.
Innovating to meet patient need
We get ahead of disease together by preventing and treating it with innovation in specialty medicines and vaccines. Our R&D approach combines our scientific focus on the immune system with the use of advanced technologies.
We’re working to deliver a new generation of differentiated medicines and vaccines in four core therapeutic areas where we have the strongest expertise, and where significant patient need remains: respiratory, immunology and inflammation; oncology, HIV; and infectious diseases.
Technology powers all aspects of our R&D. We use human genetics and functional genomics, along with artificial intelligence and machine learning (AI/ML), to deeply understand the patient, human biology, and disease mechanisms. This is leading to real breakthroughs for tackling a range of conditions, such as liver disease, or transforming HIV treatment and prevention.
We believe the powerful combination of science and technology holds the key to fundamentally transforming medical discovery for the better, making the R&D process more dynamic, improving success rates and shaping how even the most challenging diseases, like neurological conditions and cancer, can be both prevented and treated.
A Canadian R&D Leader
We are one of the largest research and development (R&D) organizations in Canada. We have invested over $146 million in Canadian research and development (R&D) in 2024.
Canada's Top 100 Corporate R&D Spenders
Supporting R&D innovation in Canada
To accelerate the discovery of new medicines and vaccines, we make collaboration part of our business model. Partnering with academic researchers and public organizations is a key part of our research efforts and we have a range of projects in place to allow us to work with and support new projects that fall within the specific areas of science we are interested in exploring.
In Canada, GSK is actively engaged in the support of research and innovation in the life sciences, and the commercialization of new technologies. GSK Canada works actively with academic researchers, university industry liaison and technology transfer offices, and innovation hubs such as the Quebec Consortium for Drug Development (CQDM) to investigate new therapeutic targets as well as disruptive platforms for discovery and development.
Our pipeline
As a global biopharma company, we invest heavily in our industry-leading pipeline of potential specialty medicines and vaccines that help us to get ahead of disease together.Therapeutic areas
The four areas of human health we focus on to get ahead of disease are: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases.
We remain open to opportunities outside these core areas where the science aligns with our strategic approach.
